Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
This has implications for clinical applications of the possible treatment to reduce carbohydrate or calorie intake, especially for the overweight and the obese
Other options may be preferable for people who: Prefer FDA-approved finished drug products: If having an FDA-approved finished product is important to you, compounded formulations - from any platform - may not align with your preferences
DG has no conflicts of interest to declare
However, careful clinical assessment is needed before initiating therapy, particularly regarding gastrointestinal function and concurrent MS medications
Recent research and observational reports have highlighted: Self-reported reductions in alcohol cravings among some individuals taking GLP-1 medications Decreases in alcohol consumption noted in limited human studies Reduced alcohol-seeking behavior observed in animal models Researchers have proposed several mechanisms that may help explain these findings, including: Modulation of dopamine signaling within reward-related brain pathways Reduced reinforcement or reward response associated with alcohol intake Altered motivation or craving intensity related to substance use It is important to note that existing studies have significant limitations, such as: Small sample sizes and short study durations Reliance on self-reported alcohol use rather than objective measures A lack of randomized, controlled clinical trials Key context to keep in mind: GLP-1 medications are not approved for the treatment of alcohol use disorder Reported effects vary widely between individuals Current evidence is insufficient to establish causation or clinical benefit Research in this area is ongoing, and no definitive conclusions can be drawn at this time
